Skip to main content
Erschienen in: Modern Rheumatology 4/2013

01.07.2013 | Original Article

Radiologic analysis of the effect of tocilizumab on hands and large joints in children with systemic juvenile idiopathic arthritis

verfasst von: Yutaka Inaba, Remi Ozawa, Chie Aoki, Tomoyuki Imagawa, Masaaki Mori, Ryoki Hara, Takako Miyamae, Tomoyuki Saito, Shumpei Yokota

Erschienen in: Modern Rheumatology | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To assess the efficacy of tocilizumab for preventing damage to the joints of systemic juvenile idiopathic arthritis (sJIA) patients, we examined serial radiographs of the hands and large weight-bearing joints of these patients before and after treatment with this agent.

Methods

Nine patients with sJIA receiving 8 mg/kg of tocilizumab intravenously every 2 weeks were studied. The mean follow-up period was 82 months. The number of active joints and laboratory markers of inflammation were assessed before and after tocilizumab treatment, together with radiologic evaluation of the hips, knees, ankles, shoulders, and elbows. The latter examination included soft tissue swelling, juxta-articular osteoporosis, epiphyseal irregularity, joint-space narrowing, cyst formation, erosion, and localized growth abnormalities. Modified Larsen scores for the large joints and the Poznanski score were also recorded.

Results

After tocilizumab treatment, the number of active joints and serum inflammatory markers decreased (p < 0.01). There was a decrease in radiologic abnormalities at the final follow-up (p < 0.01) with the exception of localized growth abnormalities. Radiologic improvement was observed in 47 joints (52 %), but ten (11 %) worsened. Total Larsen score was decreased from 15.8 to 10.9 at the final follow-up. Although the Poznanski score did not change after tocilizumab treatment, it was closely correlated with the total Larsen score (r = 0.53, p < 0.05).

Conclusions

We describe radiologic improvement of the majority of damaged large joints in sJIA following tocilizumab therapy, but some deteriorated further despite stabilization of systemic inflammatory responses. Further studies with a larger number of patients are needed.
Literatur
1.
Zurück zum Zitat Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edomonton, 2001. J Rheumatol. 2004;31:390–2.PubMed Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edomonton, 2001. J Rheumatol. 2004;31:390–2.PubMed
2.
Zurück zum Zitat De Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A. Correlation of serum interleukin 6 levels with joint involvement and thrombocytosis in systemic juvenile idiopathic arthritis. Arthritis Rheum. 1991;34:1158–63.PubMedCrossRef De Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A. Correlation of serum interleukin 6 levels with joint involvement and thrombocytosis in systemic juvenile idiopathic arthritis. Arthritis Rheum. 1991;34:1158–63.PubMedCrossRef
3.
Zurück zum Zitat Mangge H, Kenzian H, Gallistl S, Neuwirth G, Liebmann P, Kaulfersch W, et al. Serum cytokines in juvenile rheumatoid arthritis (JRA). Correlation with conventional inflammatory parameters and clinical subtypes. Arthritis Rheum. 1995;38:211–20.PubMedCrossRef Mangge H, Kenzian H, Gallistl S, Neuwirth G, Liebmann P, Kaulfersch W, et al. Serum cytokines in juvenile rheumatoid arthritis (JRA). Correlation with conventional inflammatory parameters and clinical subtypes. Arthritis Rheum. 1995;38:211–20.PubMedCrossRef
4.
Zurück zum Zitat Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003;48:1093–101.PubMedCrossRef Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003;48:1093–101.PubMedCrossRef
5.
Zurück zum Zitat Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. Clin Rheumatol. 2008;27:67–76.PubMedCrossRef Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. Clin Rheumatol. 2008;27:67–76.PubMedCrossRef
6.
Zurück zum Zitat Woo P, Wilkinson N, Prieur AM, Southwood T, Leone V, Livemore P, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther. 2005;7:R1281–8.PubMedCrossRef Woo P, Wilkinson N, Prieur AM, Southwood T, Leone V, Livemore P, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther. 2005;7:R1281–8.PubMedCrossRef
7.
Zurück zum Zitat Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, et al. Therapeutic Efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005;52:818–25.PubMedCrossRef Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, et al. Therapeutic Efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005;52:818–25.PubMedCrossRef
8.
Zurück zum Zitat Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998–1006.PubMedCrossRef Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998–1006.PubMedCrossRef
9.
Zurück zum Zitat Ilowite N, Porras O, Reiff A, Rudge S, Punaro M, Martin A, et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol. 2009;28:129–37.PubMedCrossRef Ilowite N, Porras O, Reiff A, Rudge S, Punaro M, Martin A, et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol. 2009;28:129–37.PubMedCrossRef
10.
Zurück zum Zitat Ruperto N, Quartier P, Wulffraat N, Woo P, Ravelli A, Mouy R, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 2012;64:557–67.PubMedCrossRef Ruperto N, Quartier P, Wulffraat N, Woo P, Ravelli A, Mouy R, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 2012;64:557–67.PubMedCrossRef
11.
Zurück zum Zitat Nielsen S, Ruperto N, Gerloni V, Simonini G, Cortis E, Lepore L, et al. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2008;26:688–92.PubMed Nielsen S, Ruperto N, Gerloni V, Simonini G, Cortis E, Lepore L, et al. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2008;26:688–92.PubMed
12.
Zurück zum Zitat Tse SML, Laxer RM, Babyn PS, Doria AS. Radiologic improvement of juvenile idiopathic arthritis-enthesitis-related arthritis following anti-tumor necrosis factor-α blockade with etanercept. J Rheumatol. 2006;33:1186–8.PubMed Tse SML, Laxer RM, Babyn PS, Doria AS. Radiologic improvement of juvenile idiopathic arthritis-enthesitis-related arthritis following anti-tumor necrosis factor-α blockade with etanercept. J Rheumatol. 2006;33:1186–8.PubMed
13.
Zurück zum Zitat Inaba Y, Ozawa R, Imagawa T, Mori M, Hara Y, Miyamae T, et al. Radiographic improvement of damaged large joints in children with systemic juvenile idiopathic arthritis following tocilizumab treatment. Ann Rheum Dis. 2011;70:1693–5.PubMedCrossRef Inaba Y, Ozawa R, Imagawa T, Mori M, Hara Y, Miyamae T, et al. Radiographic improvement of damaged large joints in children with systemic juvenile idiopathic arthritis following tocilizumab treatment. Ann Rheum Dis. 2011;70:1693–5.PubMedCrossRef
14.
Zurück zum Zitat Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202–9.PubMed Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202–9.PubMed
15.
Zurück zum Zitat Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum. 1994;37:1761–9.PubMedCrossRef Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum. 1994;37:1761–9.PubMedCrossRef
16.
Zurück zum Zitat Larsen A. How to apply Larsen score in evaluating radiographs of rheumatoid arthritis in long-term studies. J Rheumatol. 1995;22:1974–5.PubMed Larsen A. How to apply Larsen score in evaluating radiographs of rheumatoid arthritis in long-term studies. J Rheumatol. 1995;22:1974–5.PubMed
17.
Zurück zum Zitat Poznanski AK, Hernandez RJ, Guire KE, Bereza UL, Garn SM. Carpal length in children: a useful measurement in the diagnosis of rheumatoid arthritis and some congenital malformation syndromes. Radiology. 1978;129:661–8.PubMed Poznanski AK, Hernandez RJ, Guire KE, Bereza UL, Garn SM. Carpal length in children: a useful measurement in the diagnosis of rheumatoid arthritis and some congenital malformation syndromes. Radiology. 1978;129:661–8.PubMed
18.
Zurück zum Zitat Inamo Y, Harada K. Normal range of carpal length in Japanese children. Nihon Univ J Med. 1998;40:81–7. Inamo Y, Harada K. Normal range of carpal length in Japanese children. Nihon Univ J Med. 1998;40:81–7.
19.
Zurück zum Zitat Strand V, Cohen S, Schiff M, Weaver A, Fleischmann RM, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med. 1999;159:2542–50.PubMedCrossRef Strand V, Cohen S, Schiff M, Weaver A, Fleischmann RM, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med. 1999;159:2542–50.PubMedCrossRef
20.
Zurück zum Zitat Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002;46:1443–50.PubMedCrossRef Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002;46:1443–50.PubMedCrossRef
21.
Zurück zum Zitat Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet. 2004;363:675–81.PubMedCrossRef Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet. 2004;363:675–81.PubMedCrossRef
22.
Zurück zum Zitat Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343:1594–602.PubMedCrossRef Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343:1594–602.PubMedCrossRef
23.
Zurück zum Zitat Harel L, Wagner-weiner L, Poznanski AK, Spencer CH, Ekwo E, Magilavy DB. Effects of methotrexate on radiologic progression in juvenile rheumatoid arthritis. Arthritis Rheum. 1993;36:1370–4.PubMedCrossRef Harel L, Wagner-weiner L, Poznanski AK, Spencer CH, Ekwo E, Magilavy DB. Effects of methotrexate on radiologic progression in juvenile rheumatoid arthritis. Arthritis Rheum. 1993;36:1370–4.PubMedCrossRef
24.
Zurück zum Zitat Ravelli A, Ioseliani M, Norambuena X, Sato J, Pistorio A, Rossi F, et al. Adapted versions of the Sharp/van der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis. Arthritis Rheum. 2007;56:3087–95.PubMedCrossRef Ravelli A, Ioseliani M, Norambuena X, Sato J, Pistorio A, Rossi F, et al. Adapted versions of the Sharp/van der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis. Arthritis Rheum. 2007;56:3087–95.PubMedCrossRef
25.
Zurück zum Zitat Poznanski AK, Conway JJ, Shkolink A, Pachman LM. Radiological approaches in the evaluation of joint disease in children. Rheum Dis Clin N Am. 1987;13:57–73. Poznanski AK, Conway JJ, Shkolink A, Pachman LM. Radiological approaches in the evaluation of joint disease in children. Rheum Dis Clin N Am. 1987;13:57–73.
26.
Zurück zum Zitat Rossi F, Dia FD, Galipo O, Pistorio A, Valle M, Magni-manzoni S, et al. Use of the Sharp and Larsen scoring methods in the assessment of radiographic progression in juvenile idiopathic arthritis. Arthritis Rheum. 2006;55:717–23.PubMedCrossRef Rossi F, Dia FD, Galipo O, Pistorio A, Valle M, Magni-manzoni S, et al. Use of the Sharp and Larsen scoring methods in the assessment of radiographic progression in juvenile idiopathic arthritis. Arthritis Rheum. 2006;55:717–23.PubMedCrossRef
27.
Zurück zum Zitat Pettersson H, Rydholm U. Radiologic classification of knee joint destruction in juvenile chronic arthritis. Pediatr Radiol. 1984;14:419–21.PubMedCrossRef Pettersson H, Rydholm U. Radiologic classification of knee joint destruction in juvenile chronic arthritis. Pediatr Radiol. 1984;14:419–21.PubMedCrossRef
28.
Zurück zum Zitat Rau R, Wassenberg S, Herborn G, Perschel WT, Freitag G. Identification of radiologic healing phenomenon in patients with rheumatoid arthritis. J Rheumatol. 2001;28:2608–15.PubMed Rau R, Wassenberg S, Herborn G, Perschel WT, Freitag G. Identification of radiologic healing phenomenon in patients with rheumatoid arthritis. J Rheumatol. 2001;28:2608–15.PubMed
29.
Zurück zum Zitat Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling: emerging insights into the pathophysiology of osteoporosis. N Engl J Med. 1995;332:305–11.PubMedCrossRef Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling: emerging insights into the pathophysiology of osteoporosis. N Engl J Med. 1995;332:305–11.PubMedCrossRef
30.
Zurück zum Zitat Theoleyre S, Wittant Y, Tat SK, Fortun Y, Redini F, Heymann D. The molecular triad OPGRANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev. 2004;15:457–75.PubMedCrossRef Theoleyre S, Wittant Y, Tat SK, Fortun Y, Redini F, Heymann D. The molecular triad OPGRANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev. 2004;15:457–75.PubMedCrossRef
31.
Zurück zum Zitat Kato A, Matsuo S, Takai H, Uchiyama Y, Mihara M, Suzuki M. Early effects of tocilizumab on bone and bone marrow lesions in a collagen-induced arthritis monkey model. Exp Mol Pathol. 2008;84:262–70.PubMedCrossRef Kato A, Matsuo S, Takai H, Uchiyama Y, Mihara M, Suzuki M. Early effects of tocilizumab on bone and bone marrow lesions in a collagen-induced arthritis monkey model. Exp Mol Pathol. 2008;84:262–70.PubMedCrossRef
32.
Zurück zum Zitat Seki E, Matsushita I, Sugiyama E, Taki H, Shinoda K, Hounoki H, et al. Radiographic progression in weight-bearing joints of patients with rheumatoid arthritis after TNF-blocking therapies. Clin Rheumatol. 2009;28:453–60.PubMedCrossRef Seki E, Matsushita I, Sugiyama E, Taki H, Shinoda K, Hounoki H, et al. Radiographic progression in weight-bearing joints of patients with rheumatoid arthritis after TNF-blocking therapies. Clin Rheumatol. 2009;28:453–60.PubMedCrossRef
33.
Zurück zum Zitat Levinson JE, Wallace CA. Dismantling the pyramid. J Rheumatol Suppl. 1992;33:6–10.PubMed Levinson JE, Wallace CA. Dismantling the pyramid. J Rheumatol Suppl. 1992;33:6–10.PubMed
34.
Zurück zum Zitat Magni-manzoni S, Rossi F, Pistorio A, Temporini F, Viola S, Beluffi G, et al. Prognostic factors for radiographic progression, radiographic damage, and disability in juvenile idiopathic arthritis. Arthritis Rheum. 2003;48:3509–17.PubMedCrossRef Magni-manzoni S, Rossi F, Pistorio A, Temporini F, Viola S, Beluffi G, et al. Prognostic factors for radiographic progression, radiographic damage, and disability in juvenile idiopathic arthritis. Arthritis Rheum. 2003;48:3509–17.PubMedCrossRef
Metadaten
Titel
Radiologic analysis of the effect of tocilizumab on hands and large joints in children with systemic juvenile idiopathic arthritis
verfasst von
Yutaka Inaba
Remi Ozawa
Chie Aoki
Tomoyuki Imagawa
Masaaki Mori
Ryoki Hara
Takako Miyamae
Tomoyuki Saito
Shumpei Yokota
Publikationsdatum
01.07.2013
Verlag
Springer Japan
Erschienen in
Modern Rheumatology / Ausgabe 4/2013
Print ISSN: 1439-7595
Elektronische ISSN: 1439-7609
DOI
https://doi.org/10.1007/s10165-012-0711-0

Weitere Artikel der Ausgabe 4/2013

Modern Rheumatology 4/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.